The low-density lipoprotein cholesterol lowering is an ineffective surrogate marker of statin responsiveness to predict cardiovascular outcomes: The 10-year experience of matched population (a STROBE-compliant article)

Statins therapy decrease both low-density lipoprotein cholesterol (LDL-C) levels and the risk of atherosclerotic cardiovascular disease (ASCVD) with considerable individual variability. Whether the amount of LDL-C lowering is a surrogate maker of statin responsiveness to ASCVD prevention has not bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Hyun, Myung Han, Jang, Jae Won, Choi, Byoung Geol, Na, Jin Oh, Choi, Cheol Ung, Kim, Jin Won, Kim, Eung Ju, Rha, Seung-Woon, Park, Chang Gyu, Lee, Eunmi, Seo, Hong Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
3400
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940163/
https://www.ncbi.nlm.nih.gov/pubmed/31861037
http://dx.doi.org/10.1097/MD.0000000000018510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940163/
https://www.ncbi.nlm.nih.gov/pubmed/31861037
http://dx.doi.org/10.1097/MD.0000000000018510

Ejemplares similares